A study found that a risk calculator had no significant impact on surgeons’ decisions regarding surveillance for low-risk pancreatic intraductal papillary mucinous neoplasms (IPMNs).

• Clinicians’ estimated likelihood of progression remained unchanged (88% vs. 89% for vignettes).
• Recommendation to continue surveillance did not significantly differ (57% vs. 41% across scenarios).

Surgeons reported varying cancer risk thresholds, indicating a lack of consensus.

• Future research is needed to understand why risk calculators are ineffective in altering decision-making.